Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial

INTRODUCTION: Advanced hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) has the worst prognosis among all phenotypes. This trial aims to evaluate whether treatment with durvalumab, alone or in combination with tremelimumab, plus particle therapy is a safe and synergistically effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogasawara, Sadahisa, Koroki, Keisuke, Makishima, Hirokazu, Wakatsuki, Masaru, Takahashi, Asahi, Yumita, Sae, Nakagawa, Miyuki, Ishino, Takamasa, Ogawa, Keita, Fujiwara, Kisako, Iwanaga, Terunao, Sakuma, Takafumi, Fujita, Naoto, Kojima, Ryuta, Kanzaki, Hiroaki, Kobayashi, Kazufumi, Kiyono, Soichiro, Nakamura, Masato, Kanogawa, Naoya, Saito, Tomoko, Kondo, Takayuki, Nakagawa, Ryo, Nakamoto, Shingo, Muroyama, Ryosuke, Chiba, Tetsuhiro, Ozawa, Yoshihito, Kawasaki, Yohei, Kurokawa, Tomoya, Hanaoka, Hideki, Tsuji, Hiroshi, Kato, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995959/
https://www.ncbi.nlm.nih.gov/pubmed/35396315
http://dx.doi.org/10.1136/bmjopen-2021-059779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995959/
https://www.ncbi.nlm.nih.gov/pubmed/35396315
http://dx.doi.org/10.1136/bmjopen-2021-059779

Ejemplares similares